RAIN Earnings Prediction
The chart below shows how RAIN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RAIN sees a +0.00% change in stock price 10 days leading up to the earnings, and a +0.00% change 10 days following the report. On the earnings day itself, the stock moves by +0.00%. This data can give you a slight idea of what to expect for the next quarter's release.
RAIN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.05
--
--
No Data Available
RAIN Earnings Analysis
Rain Oncology Inc. Corporation (RAIN.O) Earnings Conference Call
Positive
Rain Oncology provided top-line data readout on the Phase 3 global registrational trial for milademetan, demonstrating a commitment to advancing innovative therapeutic strategies for cancer patients.
Data from the Phase 3 trial and future studies will contribute valuable insights into the potential efficacy of milademetan in treating dedifferentiated liposarcoma and MDM2 amplified solid tumors.
Despite the Phase 3 trial not meeting its primary endpoint, Rain Oncology swiftly initiated actions to streamline operations, reprioritize activities, and implement cost-saving measures, including a reduction in force.
These actions demonstrate the company's agile response to challenging results, ensuring judicious capital utilization and moderation of cash burn moving forward.
Rain Oncology is proactively exploring opportunities to license or acquire clinical-stage programs and technologies, highlighting a commitment to advancing novel therapeutic strategies and creating value for shareholders.
The company's corporate development team is actively reviewing numerous actionable opportunities that could potentially enhance Rain Oncology's portfolio and impact on cancer patient care.
Despite financial challenges, Rain Oncology maintained a solid cash position of $86.3 million as of June 30, 2023, providing runway into year-end 2026 without corporate transaction or partner financing.
The company's sound financial management and cost-saving efforts position it well to pursue strategic opportunities and advance its research and development efforts in the coming years.
Negative
- The Phase 3 global registrational trial for milademetan did not meet its primary endpoint, leading to the decision to suspend the enrollment of the MANTRA-2 study.
- Despite clear activity from the MANTRA-2 study, the monotherapy activity of milademetan was deemed insufficient for registrational purposes, resulting in the closure of the study to conserve capital.
- The restructuring of operations, reprioritization of activities, and implementation of cost-saving measures, including a reduction in force, were necessary following the disappointing results of the Phase 3 trial.
- The net loss for the three months ended June 30, 2023, increased to $22.1 million compared to $17.6 million for the same period in 2022, primarily driven by higher clinical trial costs and restructuring charges.
- Rain reported $86.3 million in cash, cash equivalents, and short-term investments as of June 30, 2023, indicating the need for a corporate transaction or partner financing to extend the financial runway beyond year-end 2026.
